Welcome to our dedicated page for Novanta SEC filings (Ticker: NOVT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Novanta Inc. (Nasdaq: NOVT) files a range of documents with the U.S. Securities and Exchange Commission that shed light on its operations as a global supplier of core technology solutions for medical, life science, and advanced industrial OEMs. This SEC filings page brings together those disclosures so investors can review the company’s regulatory record in one place.
Among the most frequently referenced filings are current reports on Form 8-K, where Novanta announces quarterly financial results, provides non-GAAP metrics such as Adjusted EBITDA and Adjusted Diluted EPS, and discloses material events. Recent 8-K filings have covered results for specific fiscal quarters, revisions to financial guidance, changes in Board composition, and details of share repurchase authorizations.
Filings also document capital markets and financing transactions, including the underwriting agreement and terms of Novanta’s tangible equity units offering, which combines prepaid stock purchase contracts with senior amortizing notes due 2028. Related 8-Ks describe settlement mechanics, interest and installment payments, and the listing of the units under the symbol NOVTU. Other filings outline the terms of the company’s senior credit facilities under its Fourth Amended and Restated Credit Agreement and subsequent amendments, including leverage and coverage covenants.
Through this page, users can access Novanta’s 10-K annual reports and 10-Q quarterly reports (when filed), as well as Forms 4 and other ownership-related filings, via real-time updates from EDGAR. AI-powered summaries help explain complex sections, highlight key changes from prior periods, and clarify the implications of items such as guidance revisions, credit agreement provisions, and share repurchase programs.
Whether reviewing earnings-related disclosures, tracking capital structure developments, or examining governance and compensation information, this filings hub provides a structured entry point into Novanta’s SEC reporting history.
Novanta Inc. director Thomas N. Secor reported equity-related transactions in company stock. On January 2, 2026, 1,325 Restricted Stock Units (RSUs) were settled into 1,325 shares of Novanta common stock at a reported price of $0.00 per share, leaving him with 1,325 common shares held directly. Each RSU was the economic equivalent of one common share.
On the same date, Secor was also awarded 1,799 new RSUs at a price of $0.00, with each unit representing the right to receive one Novanta common share on the first anniversary of the grant date (or the next business day). The filing notes that these RSUs were fully vested and non‑forfeitable on the grant date.
Novanta Inc. director Robert Matthew Johnson reported routine equity compensation activity. On January 2, 2026, 1,325 Restricted Stock Units (RSUs), each equivalent to one Novanta common share, were settled into 1,325 shares of common stock. After this settlement, he directly held 2,143 shares of common stock.
On the same date, Johnson was granted 1,799 new RSUs, each representing the right to receive one Novanta common share on the first anniversary of the grant date (or the next business day). These RSUs were fully vested and non‑forfeitable at grant, and he held 1,799 derivative securities (RSUs) directly following the grant.
Novanta Inc. director Lonny J. Carpenter reported equity awards and a share settlement. On January 2, 2026, he received 1,799 Restricted Stock Units (RSUs), each representing the right to receive one Novanta common share, with no cash paid per unit. On the same date, 1,325 previously held RSUs were settled into 1,325 shares of common stock, reflecting that each RSU was the economic equivalent of one common share and had become fully vested and non‑forfeitable. Following these transactions, Carpenter directly owned 5,848 shares of common stock and held 1,799 RSUs outstanding.
Novanta Inc. director reported a small stock sale under a pre-arranged trading plan. On 12/15/2025, the reporting person sold 748 shares of Novanta common stock at a price of $119.67 per share. After this transaction, the director directly beneficially owns 747 shares of Novanta common stock. The filing notes that the sale was carried out under a pre-established Rule 10b5-1 trading plan adopted on September 10, 2025, which is designed to allow insiders to sell shares according to a preset schedule.
Novanta Inc. (NOVT) revised its guidance following a recent equity issuance. The company lowered non-GAAP Adjusted Diluted EPS guidance to $0.84–$0.91 for Q4 2025 and $3.21–$3.28 for full-year 2025, compared with prior ranges of $0.87–$0.93 and $3.24–$3.30.
Revenue and Adjusted EBITDA guidance remain unchanged. GAAP revenue is still $253–$257 million for Q4 2025 and $975–$979 million for the year. Adjusted EBITDA remains $62–$65 million for Q4 and $222–$225 million for full-year 2025.
The guidance reflects higher diluted share counts from the equity issuance: an expected impact of 2.5–2.6 million shares in Q4 2025 and 0.6–0.7 million for full-year 2025, with an estimated 2026 impact of 4.7–5.9 million shares.
Novanta Inc. completed a public offering of 6.50% tangible equity units, issuing 12,650,000 Units after underwriters fully exercised their 1,650,000 over-allotment option. Each Unit was priced at $50.00 and consists of a prepaid stock purchase contract and a senior amortizing note paying quarterly installments equivalent to 6.50% per year on the $50.00 stated amount.
The purchase contracts are scheduled to settle in common shares on November 1, 2028, with early settlement features and a company early-settlement right after November 1, 2026 subject to a stock price condition. The amortizing notes bear 6.30% interest with a final installment on November 1, 2028. Novanta plans to use proceeds to strengthen its balance sheet, including repaying approximately $317 million under its revolving credit facility and for general corporate purposes. Nasdaq approved listing of the Units as NOVTU, with trading expected to begin November 12, 2025.
Separately, Novanta amended its credit agreement, raising the maximum consolidated leverage ratio to 3.75:1.00 (with an optional step-up to 4.25:1.00 following certain acquisitions) and increasing cash netting in leverage calculations to $100.0 million.
Novanta Inc. is offering 11,000,000 6.50% tangible equity units at $50.00 per Unit, with an underwriters’ option for up to 1,650,000 additional Units. Each Unit includes a prepaid stock purchase contract and a senior amortizing note due Nov 1, 2028, initially $8.74 principal, paying quarterly cash installments of $0.8125 (equivalent to 6.50% per year on the $50 stated amount).
On or before the mandatory settlement date, each purchase contract will settle into Novanta common shares based on market value, delivering between 0.3729 and 0.4662 shares per contract, with early settlement features and protections for specified corporate events. The company has applied to list the Units on Nasdaq under NOVTU; its common shares trade as NOVT.
Gross proceeds are $550,000,000, underwriting commission $15,125,000, and estimated net proceeds of $533.0 million. Novanta plans to repay approximately $317 million on its revolving facility (weighted average rate 5.32%) and use the remainder for general corporate purposes, including potential acquisitions and investments.
Novanta Inc. (NOVT) director reported a grant of 241 restricted stock units (RSUs) on 11/03/2025. Each RSU represents the right to receive one Novanta common share on the first anniversary of the grant date.
The filing states the RSUs were fully vested and non-forfeitable on the grant date, with settlement in shares one year later. Following the transaction, the reporting person held 241 derivative securities, shown as Direct (D) ownership.
Novanta Inc. (NOVT) reported an initial beneficial ownership filing on Form 3 for a board member effective 11/02/2025. The filing states that no securities are beneficially owned by the reporting person at this time. The relationship is identified as Director, and the form was filed by one reporting person. A Power of Attorney (Exhibit 24) is referenced, authorizing the attorney-in-fact to sign on the reporting person’s behalf.